




Merrimack
 Investor Relations Department
 One Kendall Square
 Suite B7201
 Cambridge, MA 02139
 United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: MACK


Last Trade:	1.17
Trade Time:	2:49 PM ET Aug 22, 2017
Change:	-0.03  (-2.101%)
Day Range	1.16 - 1.19
52-Week Range	1.13 - 6.79
Volume	574,877

Stock information is provided by eSignal,
 stock charts provided by EDGAR Online.
 Stock data is delayed approximately 20
 minutes.

Company Profile

Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Our mission is to transform cancer care through the smart design and development of targeted solutions based on the deep understanding of cancer pathways and biological markers. All of our product candidates, including three in clinical studies and several others in preclinical development, fit into our three-pronged strategy of 1) understanding the biological problems we are trying to solve, 2) designing specific solution... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 14, 2017
[Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer](#)
- Aug 9, 2017
[Merrimack Reports Second Quarter 2017 Financial Results](#)
- Aug 2, 2017
[Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call](#)
- Jul 24, 2017
[Merrimack Appoints Thomas Needham as Chief Business Officer](#)
- Jun 19, 2017
[Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018](#)

Upcoming Events [\[View all \]](#)

- Sep 7, 2017 12:15 PM ET
[Robert W. Baird 2017 Global Healthcare Conference](#)
- Jun 26, 2017
[Proxy Statement \(DEF 14A\)](#)
- Aug 9, 2017
[Quarterly Report \(10-Q\)](#)
- May 10, 2017
[Quarterly Report \(10-Q\)](#)